Sol-Gel Technologies Revenue 2016-2024 | SLGL
Sol-Gel Technologies revenue from 2016 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Sol-Gel Technologies Annual Revenue
(Millions of US $) |
| 2023 |
$2 |
| 2022 |
$4 |
| 2021 |
$31 |
| 2020 |
$9 |
| 2019 |
$23 |
| 2018 |
$0 |
| 2017 |
$0 |
| 2016 |
$ |
| 2015 |
$ |
Sol-Gel Technologies Quarterly Revenue
(Millions of US $) |
| 2024-09-30 |
$5 |
| 2024-06-30 |
$5 |
| 2024-03-31 |
$0 |
| 2023-12-31 |
$0 |
| 2023-09-30 |
$0 |
| 2023-06-30 |
$1 |
| 2023-03-31 |
$0 |
| 2022-12-31 |
$0 |
| 2022-09-30 |
$0 |
| 2022-06-30 |
$4 |
| 2022-03-31 |
$0 |
| 2021-12-31 |
$21 |
| 2021-09-30 |
$9 |
| 2021-06-30 |
$1 |
| 2021-03-31 |
$1 |
| 2020-12-31 |
$2 |
| 2020-09-30 |
$2 |
| 2020-06-30 |
$1 |
| 2020-03-31 |
$3 |
| 2019-12-31 |
$4 |
| 2019-09-30 |
$5 |
| 2019-06-30 |
$8 |
| 2019-03-31 |
$6 |
| 2018-12-31 |
$-0 |
| 2018-09-30 |
$0 |
| 2018-06-30 |
$0 |
| 2018-03-31 |
$0 |
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.027B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
